Texans For Greater Mental Health

What Texans For Greater Mental Health does

Texans for Greater Mental Health (T4GMH) is a 501(c)(3) nonprofit public charity (Tax ID: 88-4314040) headquartered in Austin, Texas, operating as a policy advocacy organization rather than a commercial technology company. Founded approximately 2022, T4GMH serves as the originating force of state-level psychedelic policy reform in the United States, instrumental in passing House Bill 1802 (2021) to fund the first publicly backed psilocybin for PTSD clinical trial since the Controlled Substances Act and in supporting Senate Bill 2308 (2025), which created the Texas Ibogaine Initiative with $100 million in public funding. Its "products" are advocacy and policy initiatives: legislative advocacy programs, stakeholder engagement, community education and public events, and direct policy work, all backed by a multi-channel digital presence (website, newsletter, social platforms, podcast appearances) rather than a proprietary technology platform.

The organization generates revenue exclusively through charitable donations from individuals, foundations, and supporters, and states that no funds are used for payroll or administration. Its value proposition is the mobilization of science-backed advocacy to expand access to psychedelic-assisted therapies for treatment-resistant PTSD, opioid addiction, traumatic brain injury, and related conditions, primarily serving Veterans, first responders, and individuals with severe mental health conditions. Its go-to-market is bipartisan coalition-building with Texas legislators, academic medical centers (Baylor College of Medicine, UTMB Health, UTHealth Houston, Dell Medical School's McGill Center), and former Governor Rick Perry, plus federal-level engagement that contributed to the April 2026 Trump Administration Executive Order citing Texas as a national model and unlocking $50M+ through ARPA-H for state-federal psychedelic research partnerships.

Operational scale is intentionally lean: leadership comprises a Founder and Board President (Eric Khozindar), Co-Executive Directors (Mary Olivar and Vance McMurry), a Senior Advisor and Policy Director (former founding Executive Director Logan Davidson, transitioned end of 2025), a General Counsel, and directors for social media and operations/events, with Nate Benson serving as interim Executive Director during a national search. The Board includes Steven Davidson, Alex Dominguez (HB 1802's legislative author), Tipton Horn, Dani Neff, Reese Ormand, Rick Rosenblum, and Katherine Willis. T4GMH describes itself as having unlocked nearly $100 million for psychedelic research across state and federal efforts, though these are research grants routed to academic partners rather than the charity's own receipts, a critical distinction for any financial assessment.

Name

Texans For Greater Mental Health

Legal name

Texans for Greater Mental Health

Website

https://t4gmh.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Texans for Greater Mental Health is a 501(c)(3) nonprofit advocacy organization based in Austin, Texas, advancing state and federal psychedelic research and access policy. It serves veterans, first responders, and individuals with PTSD, addiction, and traumatic brain injury through legislative advocacy, coalition-building, and education, anchored by its authorship of HB 1802 and the Texas Ibogaine Initiative.

Ownership category

akta.pro rank

Product category

Mental Health Policy Advocacy

NAICS

Social Advocacy Organizations (8133)

SIC

Services-Social Services (8300), Services-Health Services (8000)

akta.pro primary industry

Substance Use Disorder Prevention & Recovery Services (BPAGACAE)

akta.pro secondary industries

Substance Use Recovery & Harm Reduction Support Services (BPAGAEAO), Behavioral Health & Substance Use Public Health Programs (BPAIAJAK), Behavioral Health & Substance Use Program Funding (Public Health) (HLAJALAI)

Keywords

• Psychedelic policy advocacy
• Mental health reform
• Drug policy nonprofit
• Psychedelic research funding
• Veteran mental health

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Donations and Charitable Contributions: Texans for Greater Mental Health is a 501(c)(3) nonprofit public charity (Tax ID: 88-4314040) that generates revenue through donations from individuals, foundations, and supporters. The organization states that donations directly support psychedelic policy advocacy and that not one cent is used for payroll or administration.

Distribution channels2 records

Marketing channels5 records

Core offering

Texans for Greater Mental Health is a 501(c)(3) nonprofit public charity that advocates for evidence-based psychedelic policy reform and expanded access to psychedelic-assisted mental health therapies. Its core offerings center on legislative advocacy campaigns (notably HB 1802 supporting the first U.S. psilocybin clinical trial for PTSD in veterans, and the Texas Ibogaine Initiative supporting FDA-approved ibogaine clinical trials), stakeholder and coalition engagement with researchers and legislators, and public education on psychedelic therapies for veterans, first responders, and individuals with treatment-resistant mental health conditions.

Product overview

Texans for Greater Mental Health is a 501(c)(3) nonprofit public charity functioning as a policy advocacy organization rather than a commercial product company. Its offerings consist of advocacy programs and legislative initiatives: HB 1802 (psilocybin research program), the Texas Ibogaine Initiative (ibogaine clinical trials), and stakeholder engagement, community education, and public policy advocacy programs. These initiatives work together to advance evidence-based psychedelic research and shape policies expanding access to mental health treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• HB 1802 Advocacy & Psilocybin Research Program Legislative advocacy program supporting Texas House Bill 1802, which established the first publicly funded psilocybin clinical trial for PTSD in U.S. veterans. The program is aimed at veterans and policymakers and supports the trial conducted by Baylor College of Medicine with HHSC and a Veterans medical center.
• Texas Ibogaine Initiative First-of-its-kind public-private collaboration advancing FDA clinical trials of ibogaine for Opioid Use Disorder and co-occurring conditions, in partnership with former Governor Rick Perry and a coalition of experts. Includes a $50 million state award to a statewide research consortium led by UTMB Health and UTHealth Houston. Aimed at policymakers, researchers, and individuals with opioid addiction and related conditions.
• Public Policy Advocacy Collaborating with partners and stakeholders to drive psychedelic policy reform, achieving legislative victories that set precedent beyond Texas. Aimed at legislators, policymakers, and institutional partners.
• Stakeholder Engagement & Policy Development Engages leaders in psychedelic research, mental health, and public policy to shape science-driven, research-first psychedelic policy. Aimed at researchers, clinicians, and legislators.
• Community Engagement & Education Organizes events, webinars, and public engagement campaigns to connect the psychedelic research community, policymakers, and the public. Aimed at donors, supporters, veterans, first responders, and the general public.

Quantifiable outcome

• Five states and federal government have replicated Texas approach to psychedelic research
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

17 partnerships are on record, tiered core and flagship.

• Trump Administration / Federal GovernmentcoreStrategic or Co-development Partner · 18 April 2026President Trump signed Executive Order directing FDA to expedite psychedelic compound review and DEA to establish access pathways. The order explicitly cited Texas program as national model and positions Texas to receive federal funding through ARPA-H federal-state partnerships. T4GMH central advocate across these federal efforts.
• University of Texas Medical Branch at Galveston (UTMB Health)coreStrategic or Co-development Partner · 12 December 2025UTMB Health leads a statewide research consortium awarded $50 million by the State of Texas to conduct clinical trials evaluating ibogaine for addiction, PTSD, traumatic brain injury, and related behavioral health conditions. T4GMH has been a central advocate in establishing this consortium.
• UTHealth HoustoncoreStrategic or Co-development Partner · 12 December 2025UTHealth Houston co-leads the statewide $50 million ibogaine research consortium alongside UTMB Health, conducting clinical trials for addiction, PTSD, and related conditions.
• Charmaine and Gordon McGill Center for Psychedelic Research and TherapycoreStrategic or Co-development Partner · 12 December 2025The McGill Center at Dell Medical School (UT Austin) played a foundational role in shaping Texas and national psychedelic research landscape. Its research helped transform legislative understanding of psychedelic-assisted therapies and was crucial to passage of Texas Ibogaine Initiative (SB 2308). Co-directed by Dr. Greg Fonzo and Dr. Charles B. Nemeroff.
• Texas Tech UniversityflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million. One of multiple Texas academic institutions collaborating on psychedelic clinical trials.
• Texas Tech University Health Sciences Center El PasoflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• The University of Texas at AustinflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million. Home to the McGill Center for Psychedelic Research and Therapy.
• The University of Texas Health Science Center at San AntonioflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• The University of Texas at TylerflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• The University of Texas Rio Grande ValleyflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• Texas A&M UniversityflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• The University of North Texas Health Science CenterflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• JPS Health Network in DallasflagshipStrategic or Co-development Partner · 12 December 2025Part of the statewide ibogaine research consortium awarded $50 million.
• VETS (Veterans Exploring Treatment Solutions)coreStrategic or Co-development Partner · 1 January 2025Logan Davidson serves as Legislative Director at VETS while also serving as Senior Advisor and Policy Director at T4GMH. VETS and T4GMH collaborate on psychedelic policy and veteran mental health advocacy.
• Texas Ibogaine InitiativecoreStrategic or Co-development Partner · 1 January 2023Partnership with former Governor Rick Perry and coalition of experts to advance FDA clinical trials of Ibogaine for Opioid Use Disorder. This public-private collaboration secured $50 million in state funding for first-of-its-kind ibogaine research.
• Former Governor Rick PerrycoreStrategic or Co-development Partner · 1 January 2023Partnered with T4GMH and coalition of experts on Texas Ibogaine Initiative to advance FDA clinical trials of Ibogaine for Opioid Use Disorder and co-occurring conditions.
• Baylor College of MedicinecoreStrategic or Co-development Partner · 1 January 2021Baylor College of Medicine is the only institution already conducting state-funded psychedelic research under HB 1802 (2021). Included in the new $50 million consortium. Dr. Lynnette Averill serves as T4GMH Advisory Board Member.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Others

• Psychedelic Alpha: Independent research and media platform covering the psychedelic industry. Comparable as an ecosystem participant shaping policy discourse and stakeholder education around psychedelics.

Direct peers

• Multidisciplinary Association for Psychedelic Studies (MAPS): The leading psychedelic research and education nonprofit in the US, advancing FDA-approved MDMA-assisted therapy. Directly comparable as a policy/advocacy nonprofit operating in psychedelic research reform with similar donation-based funding.
• Psychedelic Science Funders Collaborative: Philanthropic collaborative funding psychedelic research and policy reform. Comparable as an ecosystem player supporting both scientific research and policy advocacy in psychedelics.
• Veterans Exploring Treatment Solutions (VETS): Veteran-focused nonprofit advocating for psychedelic-assisted therapy access. Already a partner of T4GMH and most comparable on the veteran mental health and policy advocacy intersection.
• Usona Institute: Nonprofit medical research organization sponsoring psilocybin clinical trials. Comparable as a psychedelic-focused nonprofit advancing clinical research and policy.
• Chacruna Institute: Nonprofit fostering conversations about psychedelic plant medicines, including advocacy and education. Comparable as a psychedelic-policy-adjacent advocacy and public education organization.
• Heroic Hearts Project: Veteran-focused nonprofit connecting former military members with psychedelic therapy programs. Comparable to T4GMH in targeting veterans with PTSD and advocating for psychedelic treatment access.

Emerging players

• Reason for Hope: Advocacy nonprofit focused on expanding access to psychedelic therapies, particularly ibogaine. Direct topical overlap with T4GMH's Texas Ibogaine Initiative focus area.

Broad incumbents

• Compass Pathways: Publicly listed mental health care company developing psilocybin therapy for treatment-resistant depression. Indirect comparable as a leading institutional player in psychedelic-assisted therapy commercialization.
• Drug Policy Alliance: Larger, more established drug policy reform nonprofit with a broader drug-decriminalization mandate. Comparable as a policy advocacy nonprofit influencing state and federal drug legislation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/T4GMH
• YouTubeyoutube.com/@t4gmh
• Facebookfacebook.com/people/Texans-For-Greater-Mental-Health/100091419856649
• LinkedInlinkedin.com/company/texans-for-greater-mental-health
• Instagraminstagram.com/t4gmh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Texans For Greater Mental Health